文献速递妇科生殖医学

抗苗勒管激素作为未满足超声多囊卵巢形态标准女性的补充检测

Anti-Müllerian hormone as a supplementary test in women not meeting ultrasonographic polycystic ovary morphology criteria.
PubMed 文献 · Reprod Biomed Online · 2026-07-06

这项横断面研究分析了213名月经不规律或高雄激素血症女性,其中118名未满足更新的超声多囊卵巢形态(PCOM)标准。在这118名女性中,75.4%满足韩国女性年龄组特异性AMH cut-off,其代谢和雄激素特征与超声确诊的PCOS女性相似,而与对照组不同。结论认为,对超声PCOM阴性的症状女性,补充AMH检测有助于诊断PCOS并早期干预代谢风险。

要点

  • 超声PCOM阴性但症状存在的女性中,75.4%可通过AMH cut-off识别为PCOS。
  • AMH定义的PCOS女性代谢和雄激素特征与超声确诊PCOS相似。
  • 超声PCOM已明确时无需额外AMH检测,但超声阴性症状女性应考虑AMH检测。

核心结论

  • 对未满足更新超声PCOM标准的症状女性,补充AMH检测有价值,可诊断PCOS并识别代谢风险。
  • 当超声PCOM已明显时,额外AMH检测不必要,因为AMH升高已普遍存在。

研究设计与样本

  • 横断面研究分析213名月经不规律或高雄激素血症女性,均符合原Rotterdam PCOM标准。
  • 95名满足更新超声PCOM标准并诊断PCOS,剩余118名未满足更新超声标准作为主要分析组。

主要发现

  • 118名女性中75.4%(n=89)满足韩国女性年龄组特异性AMH cut-off,几何平均AMH浓度为9.8 ng/ml。
  • 这89名女性腰围、血压、HbA1c和血脂谱显著差于267名匹配对照。
  • 这89名女性的代谢和雄激素模式与95名超声PCOM诊断的PCOS女性相当,后者中93.7%(n=89)也满足AMH-based PCOM标准。

关键数值与推荐

  • 118名未满足更新超声PCOM标准的女性中,75.4%(n=89)满足韩国女性年龄组特异性AMH cut-off。
  • 95名超声PCOM诊断的PCOS女性中,93.7%(n=89)满足AMH-based PCOM标准。

临床怎么用

  • 对超声PCOM阴性的症状女性,考虑补充AMH检测以诊断PCOS并早期代谢干预。
  • 超声PCOM已明确时,无需额外AMH检测以避免过度诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Is supplementary anti-Müllerian hormone (AMH) testing of diagnostic value in symptomatic women who fail to meet the updated ultrasonographic (USG) polycystic ovary morphology (PCOM) criteria? DESIGN: Cross-sectional study analysing 213 women with irregular menstruation or hyperandrogenism who met the original Rotterdam PCOM criteria. Although 95 met the updated USG-PCOM criteria and were diagnosed with polycystic ovary syndrome (PCOS), the remaining 118 failed to meet the updated USG criteria and served as the main analysis group. RESULTS: Among the 118 women, 75.4% (n = 89) met the optimal age-group-specific and AMH cut-off for Korean women, and their geometric mean AMH concentration was 9.8 ng/ml. These 89 individuals demonstrated significantly higher waist circumference, blood pressure, haemoglobin A1c concentrations and worse lipid profiles than 267 matched controls. Their metabolic and androgenic patterns were comparable to the 95 women diagnosed with PCOS via USG-PCOM, of whom 93.7% (n = 89) also fulfilled the AMH-based PCOM criteria. CONCLUSIONS: Although concurrent use of AMH and USG is discouraged to prevent overdiagnosis, supplementary AMH testing is valuable for symptomatic women who fail to meet the updated USG-PCOM criteria. When AMH defines PCOM, these women can be diagnosed with PCOS, exhibiting clinical and metabolic features similar to USG-confirmed PCOS and distinct from controls. Additional AMH testing is unnecessary when USG-PCOM is already evident, as AMH elevation is predominantly present; however, it should be considered in USG-negative symptomatic women. Identifying these patients enables earlier metabolic intervention, potentially outweighing overdiagnosis risks.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Lee D, Hwang KR, Kim S, et al. Anti-Müllerian hormone as a supplementary test in women not meeting ultrasonographic polycystic ovary morphology criteria. Reprod Biomed Online. 2026. PMID: 42566878. doi:10.1016/j.rbmo.2026.105863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。